CA2266015C - Tricyclic antitumor compounds being farnesyl protein transferase inhibitors - Google Patents
Tricyclic antitumor compounds being farnesyl protein transferase inhibitors Download PDFInfo
- Publication number
- CA2266015C CA2266015C CA002266015A CA2266015A CA2266015C CA 2266015 C CA2266015 C CA 2266015C CA 002266015 A CA002266015 A CA 002266015A CA 2266015 A CA2266015 A CA 2266015A CA 2266015 C CA2266015 C CA 2266015C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- tumor cells
- cells
- title compound
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CS(NCC(C(CCC1)CCC1C1c2ncc(*)cc2CCc2cc(Cl)cc(Cl)c12)=O)(=O)=O Chemical compound CS(NCC(C(CCC1)CCC1C1c2ncc(*)cc2CCc2cc(Cl)cc(Cl)c12)=O)(=O)=O 0.000 description 3
- KIMAPLXVHRXDCK-UHFFFAOYSA-N Bc1cnc(C(C(CC2)CCN2C(CCCCC2C(CNc(cc3)ccc3Cl)C2)=O)c(c(CC2)cc(C)c3)c3Cl)c2c1 Chemical compound Bc1cnc(C(C(CC2)CCN2C(CCCCC2C(CNc(cc3)ccc3Cl)C2)=O)c(c(CC2)cc(C)c3)c3Cl)c2c1 KIMAPLXVHRXDCK-UHFFFAOYSA-N 0.000 description 1
- KOIUHRZZWSARLH-UHFFFAOYSA-N Bc1cnc(C(C(CC2)CCN2C(CCCNS(C)=O)=O)c(c(Cl)c2)c(CC3)cc2Cl)c3c1 Chemical compound Bc1cnc(C(C(CC2)CCN2C(CCCNS(C)=O)=O)c(c(Cl)c2)c(CC3)cc2Cl)c3c1 KOIUHRZZWSARLH-UHFFFAOYSA-N 0.000 description 1
- GTTALPVKBQRTMJ-UHFFFAOYSA-N CN(C)C(CCC(N(CC1)CCC1C(c(c(Cl)c1)c(CCc2c3)cc1Cl)c2ncc3S)=O)=O Chemical compound CN(C)C(CCC(N(CC1)CCC1C(c(c(Cl)c1)c(CCc2c3)cc1Cl)c2ncc3S)=O)=O GTTALPVKBQRTMJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71298996A | 1996-09-13 | 1996-09-13 | |
| US08/712,989 | 1996-09-13 | ||
| US87740097A | 1997-06-17 | 1997-06-17 | |
| US08/877,400 | 1997-06-17 | ||
| PCT/US1997/015899 WO1998011092A1 (en) | 1996-09-13 | 1997-09-11 | Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2266015A1 CA2266015A1 (en) | 1998-03-19 |
| CA2266015C true CA2266015C (en) | 2003-12-30 |
Family
ID=27108923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002266015A Expired - Fee Related CA2266015C (en) | 1996-09-13 | 1997-09-11 | Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0929544B1 (enExample) |
| JP (1) | JP2001521489A (enExample) |
| KR (1) | KR20000036111A (enExample) |
| CN (1) | CN1238770A (enExample) |
| AT (1) | ATE282036T1 (enExample) |
| AU (1) | AU4801197A (enExample) |
| CA (1) | CA2266015C (enExample) |
| DE (1) | DE69731544T2 (enExample) |
| ES (1) | ES2229340T3 (enExample) |
| HU (1) | HUP0001109A2 (enExample) |
| IL (1) | IL128931A0 (enExample) |
| WO (1) | WO1998011092A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ501617A (en) * | 1997-06-17 | 2001-09-28 | Schering Corp | 4-(5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-piperidine derivatives useful for inhibition of farnesyl protein transferase |
| ATE276250T1 (de) * | 1997-06-17 | 2004-10-15 | Schering Corp | Benzo(5,6)cyclohepta(1,2-b)pyridin derivate anwendbar als farnesyl protein tranferase inhibitoren |
| US5925639A (en) * | 1997-06-17 | 1999-07-20 | Schering Corporation | Keto amide derivatives useful as farnesyl protein transferase inhibitors |
| US6211193B1 (en) | 1997-06-17 | 2001-04-03 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US6218401B1 (en) | 1997-06-17 | 2001-04-17 | Schering Corporation | Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase |
| US6228865B1 (en) | 1997-06-17 | 2001-05-08 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US5852034A (en) * | 1997-06-17 | 1998-12-22 | Schering Corporation | Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors |
| US6613905B1 (en) | 1998-01-21 | 2003-09-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| CN1289336A (zh) | 1998-01-21 | 2001-03-28 | 千禧药品公司 | 趋化因子受体拮抗剂和其使用方法 |
| US6509346B2 (en) | 1998-01-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| EP1047675A1 (en) | 1998-01-21 | 2000-11-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| AU4387699A (en) * | 1998-07-24 | 2000-02-14 | Russinsky Limited | A process for preparing benzocycloheptapyridin-11-ones |
| US7271176B2 (en) | 1998-09-04 | 2007-09-18 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use thereof |
| US6288083B1 (en) | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US6503926B2 (en) | 1998-09-04 | 2003-01-07 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US6262216B1 (en) | 1998-10-13 | 2001-07-17 | Affymetrix, Inc. | Functionalized silicon compounds and methods for their synthesis and use |
| EP1296949A2 (en) | 2000-06-21 | 2003-04-02 | Bristol-Myers Squibb Pharma Company | Piperidine amides as modulators of chemokine receptor activity |
| US7342016B2 (en) | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| US7541365B2 (en) | 2001-11-21 | 2009-06-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| ATE365157T1 (de) * | 2002-10-03 | 2007-07-15 | Schering Corp | Enantioselective alkylierung von trizyklischen verbindungen |
| TWI291467B (en) | 2002-11-13 | 2007-12-21 | Millennium Pharm Inc | CCR1 antagonists and methods of use therefor |
| DE60332862D1 (de) * | 2002-11-18 | 2010-07-15 | Schering Corp | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen |
| US7417026B2 (en) | 2003-08-13 | 2008-08-26 | Children's Hospital Medical Center | Mobilization of hematopoietic cells |
| JP4769082B2 (ja) * | 2003-12-17 | 2011-09-07 | 武田薬品工業株式会社 | ウレア誘導体、その製造法及び用途 |
| JP2007529555A (ja) * | 2004-03-18 | 2007-10-25 | ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド | シヌクレイノパチーを治療する方法 |
| CN113549072B (zh) * | 2020-04-23 | 2024-12-06 | 鲁南制药集团股份有限公司 | 一种托法替布杂质ⅰ的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826853A (en) * | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
| US5089496A (en) * | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| KR920014799A (ko) * | 1991-01-18 | 1992-08-25 | 나오가따 다이도 | 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제 |
| US5721236A (en) * | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| IL111235A (en) * | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
| ATE210652T1 (de) * | 1993-10-15 | 2001-12-15 | Schering Corp | Tricyclische carbamat-derivate zur inhibierung der g-protein funktion und für die behandlung von proliferativen erkrankungen |
| US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| US5700806A (en) * | 1995-03-24 | 1997-12-23 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| IL117798A (en) * | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
| US5712280A (en) * | 1995-04-07 | 1998-01-27 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| EP1380581A1 (en) * | 1995-12-22 | 2004-01-14 | Schering Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative diseases |
-
1997
- 1997-09-11 AT AT97910710T patent/ATE282036T1/de not_active IP Right Cessation
- 1997-09-11 CN CN97199602A patent/CN1238770A/zh active Pending
- 1997-09-11 KR KR1019997002134A patent/KR20000036111A/ko not_active Withdrawn
- 1997-09-11 DE DE69731544T patent/DE69731544T2/de not_active Expired - Fee Related
- 1997-09-11 WO PCT/US1997/015899 patent/WO1998011092A1/en not_active Ceased
- 1997-09-11 IL IL12893197A patent/IL128931A0/xx unknown
- 1997-09-11 EP EP97910710A patent/EP0929544B1/en not_active Expired - Lifetime
- 1997-09-11 ES ES97910710T patent/ES2229340T3/es not_active Expired - Lifetime
- 1997-09-11 CA CA002266015A patent/CA2266015C/en not_active Expired - Fee Related
- 1997-09-11 HU HU0001109A patent/HUP0001109A2/hu unknown
- 1997-09-11 JP JP51375898A patent/JP2001521489A/ja not_active Ceased
- 1997-09-11 AU AU48011/97A patent/AU4801197A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001521489A (ja) | 2001-11-06 |
| HK1018446A1 (en) | 1999-12-24 |
| KR20000036111A (ko) | 2000-06-26 |
| CA2266015A1 (en) | 1998-03-19 |
| IL128931A0 (en) | 2000-02-17 |
| WO1998011092A1 (en) | 1998-03-19 |
| DE69731544D1 (de) | 2004-12-16 |
| AU4801197A (en) | 1998-04-02 |
| HUP0001109A2 (hu) | 2001-04-28 |
| EP0929544A1 (en) | 1999-07-21 |
| EP0929544B1 (en) | 2004-11-10 |
| ES2229340T3 (es) | 2005-04-16 |
| ATE282036T1 (de) | 2004-11-15 |
| CN1238770A (zh) | 1999-12-15 |
| DE69731544T2 (de) | 2005-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2266015C (en) | Tricyclic antitumor compounds being farnesyl protein transferase inhibitors | |
| US6277854B1 (en) | Tricyclic antitumor farnesyl protein transferase inhibitors | |
| US5661152A (en) | Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | |
| US6300338B1 (en) | Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases | |
| AU699043B2 (en) | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | |
| US5712280A (en) | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | |
| AU698960B2 (en) | Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases | |
| AU700246B2 (en) | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | |
| US6492381B1 (en) | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases | |
| EP0815099B1 (en) | Tricyclic amide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases | |
| CA2240846C (en) | Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases | |
| EP0931079B1 (en) | Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase | |
| EP0989978B1 (en) | Tricyclic keto amide derivatives useful as farnesyl protein transferase inhibitors | |
| HK1018446B (en) | Tricyclic antitumor compounds being farnesyl protein transferase inhibitors | |
| AU753533B2 (en) | Benzo(5,6)cyclohepta(1,2B)pyridine derivatives useful for inhibition of farnesyl protein transferase | |
| AU754066B2 (en) | Benzo(5,6)cyclohepta(1,2B)pyridine derivatives useful for inhibition of farnesyl protein transferase | |
| HK1028238B (en) | Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |